Physician profile
Rayann Jaber
NPI 1649040221
$952.43
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299.92 | 2024 | |
| Janssen Biotech, INC. | $134.08 | 2024 | Tremfya, Stelara |
| Genzyme Corporation | $112.64 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.41 | 2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $75.02 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $43.35 | 2024 | |
| Pfizer INC. | $40.45 | 2024 | |
| Aimmune Therapeutics, INC. | $29.63 | 2024 | |
| Madrigal Pharmaceuticals | $28.77 | 2024 | Resmetirom |
| Intercept Pharmaceuticals, INC. | $25.80 | 2024 | |
| Lilly USA, LLC | $25.69 | 2024 | Omvoh |
| Celltrion USA INC. | $21.92 | 2024 | Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $17.75 | 2024 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rayann Jaber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.